H
Huarong Biotechnology
Bio-synthesized functional raw materials for multiple industries
About Huarong Biotechnology
Founded in 2012, Luoyang Huarong Biotechnology Co., Ltd. is a Chinese high-tech enterprise specializing in the research, development, and manufacturing of bio-synthesized functional raw materials. The company utilizes synthetic biology and green biological manufacturing technologies, including enzyme catalysis and metabolic engineering, to produce its offerings.
Read full description
The company's business model is centered on the production and global supply of key ingredients for various sectors. Its product portfolio includes pharmaceutical intermediates, sports nutrition supplements, and personal care ingredients. Huarong Biotechnology serves a global client base, with over 95% of its products exported to markets in Europe, America, and Southeast Asia. The company acts as a major supplier for several international brands.
Headquartered in Luoyang, Henan province, the company has grown to over 160 employees, with a significant research and development team of more than 40 professionals. Huarong Biotechnology has received numerous accolades, including being named a National-Level "Little Giant" Enterprise and a High-Tech Enterprise in China. A key milestone was the establishment of the National Synthetic Biotechnology Innovation Center Demonstration Base for Technology Commercialization, which became operational in August 2023. In early 2026, the company completed a Series A financing round of over RMB 100 million from investors including Hongbo Capital, Guohong Capital, Guosheng Group, and Wins Finance.
At a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Luoyang, China
- Open positions
- None listed
- Dealroom signal
- 17.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Synthetic Biology, Biotech and Pharma, Bioeconomy, Techbio, biomanufacturing, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Huarong Biotechnology.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2026 | $14M | $55M | Guosheng Group · Guohong Capital · Wen's Investment · Hongbo Capital | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Guosheng Group- GCGuohong Capital
- WIWen's Investment
- HCHongbo Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Huarong Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Huarong Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.